vRad, NightHawk Radiology announce completion of merger

Virtual Radiologic (vRad) and NightHawk Radiology (Nasdaq: NHWK) today announced the completion of their previously announced merger, with NightHawk continuing as a wholly owned subsidiary of vRad. Under the terms of the merger agreement, vRad, a technology-enabled national radiology practice and leader in the development of radiologist workflow technology, acquired all of the outstanding shares of NightHawk for $6.50 per share in cash. Following the transaction, the companies will provide enhanced services to radiology groups and hospitals nationwide, accelerating vRad's stated commitment to optimize radiology's critical role in the delivery of patient care.

vRad and NightHawk merged in recognition of the widespread market need to deliver the highest quality patient care in the most efficient manner possible. The combined organization will offer radiology practices and hospitals access to 325 affiliated radiologists, over 75% of which are fellowship-trained subspecialists. These radiologists will serve nearly 2,700 healthcare facilities across all 50 states, and will read in excess of 7 million studies annually.

"The scope of our services has grown beyond just offering off-hours preliminary reads. Today's healthcare environment demands increasing access to subspecialists, along with technology-enabled, efficient workflow," said Eduard Michel, MD, Neuroradiologist, Chief Medical Officer and vRad co-founder. "It's exciting to offer the depth of subspecialty expertise of our combined practices."

"Our clients' need for expanded access, improved quality and reduced cost is clear. This combination brings together both companies' talented team members and affiliated radiologists. It will enhance the quality of patient care across the United States, and improve the efficiency of delivering it," said vRad President and Chief Executive Officer Rob Kill. "Additionally, both companies have publicly committed to partnering with our local radiologist clients, not competing with them. That commitment remains a fundamental component of our business strategy," said Kill.

With the closing of the transaction, NightHawk's common stock will cease to trade on NASDAQ at market close today and will be delisted. Letters of transmittal allowing former NightHawk stockholders to deliver their shares to the paying agent in exchange for payment of the merger consideration will be distributed promptly.

For more information about vRad's products and services, please visit www.vrad.com, email [email protected] or call (800) 737-0610.

In conjunction with the merger, a senior secured credit facility was provided by GE Capital, Healthcare Financial Services, as administrative agent (GE Capital Markets, Inc., as Joint Lead Arranger), and SunTrust Bank as syndication agent (SunTrust Robinson Humphrey as Joint Lead Arranger). Morgan Stanley & Co., Incorporated, served as NightHawk's financial advisor. Wilson Sonsini Goodrich & Rosati, Professional Corporation, served as legal counsel to NightHawk. Weil, Gotshal & Manges LLP served as legal counsel to vRad. KPMG LLP provided transaction and tax advisory services to vRad.

Source:

Virtual Radiologic

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies key metric for safe blood brain barrier opening in glioblastoma patients